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It is now accepted that, in addition to left ventricular 
hypertrophy, hypertensive heart disease is characterized by 
alterations in myocardial structure, leading to loss of tissue 
homogeneity and pathological remodelling. It is time to 
recognize that, in hypertensive heart disease, it is not only the 
quantity but also the quality of the myocardium that is 
responsible for adverse cardiovascular events. The data 
reviewed here indicate that, in patients with hypertensive h art 
disease, myocardial fibrosis predisposes to an enhanced risk for 
diastolic and/or systolic ventricular dysfunction, symptomatic 
heart failure, ischaemic heart disease and arrhythmias. 
(Eur Heart J Supplements 2002; 4 (Suppl D): D18-D22) 
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Introduction 
A growing body of evidence indicates that myocardial 
fibrosis is among the key pathological features of myocardial 
remodelling in hypertensive heart disease. Indeed, studies 
performed in post-mortem human hearts[ 1] and human 
endomyocardial biopsies[ 2] show that myocardial collagen 
volume fraction (a morphometric measure of the amount of 
tissue collagen) is consistently greater in patients with 
hypertensive heart disease than in normotensive control 
individuals. Furthermore, in patients with hypertensive heart 
disease, immunohistochemical analyses show exaggerated 
accumulation of fibrillar collagen types I and III within the 
myocardial interstitium and surrounding intra-mural 
coronary arteries and arterioles. 
The present brief review focuses on the pathophysiology 
of hypertensive myocardial fibrosis and its detrimental 
impact on cardiac function. It also discusses the non- 
invasive diagnostic tools that are currently under evaluation 
to detect myocardial fibrosis, and the evidence for its 
reparation in patients with hypertensive heart disease. 
Correspondence: Dr Javier Diez, Divisidn de Fisiopatologia 
Cardiovascular, Facultad de Medicina, C/ Irunlarrea s/n, 31080 
Pamplona, Spain. 
Multifactorial origin 
It has been proposed that the excess of myocardial collagen 
seen in hypertension is the result of both increased collagen 
synthesis and unchanged or decreased collagen 
degradation[3]. This hypothesis is supported by recent 
experimental findings that show upregulation of the pro- 
collagen type I gene[43 and diminished collagenase 
activity[ s] in the hypertrophied and fibrotic left ventricles of 
adult spontaneously hypertensive rats. Various factors 
(haemodynamic, humoral and genetic) may account for this 
disequilibrium (Fig. 1). 
Haemodynamic fa tors 
In-vivo experiments have shown that chronic pressure 
overload stimulates both pro-collagen gene expression and 
collagen protein synthesis, leading to excessive collagen 
deposition and fibrosis[6]. In addition, in-vitro studies have 
shown that pro-collagen type I synthesis is stimulated in 
cardiac fibroblasts ubjected to cyclic mechanical load[61. 
Thus, haemodynamic overload of the left ventricle due to 
systemic hypertension may play a role in myocardial 
fibrosis. 
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Figure 1 Proposed events leading 
to myocardial fibrosis in patients 
with arterial hypertension. 
Humoral factors 
In addition to haemodynamic factors, non-haemodynamic 
factors may also contribute to myocardial fibrosis in human 
hypertension, as suggested by two types of finding. First, 
post-mortem studies conducted in human hypertensive heart 
disease have identified myocardial fibrosis not only in the 
left ventricle but also in the right ventricle[ 71 and the inter- 
ventricular septum[8]. Second, recent studies have shown 
that antihypertensive agents can cause regression of biopsy- 
proven myocardial fibrosis in hypertensive patients, 
independent of antihypertensive efficacy[9,1°]. 
Thus, the current view is that myocardial fibrosis may 
result from the loss of reciprocal regulation that normally 
exists between molecules that stimulate and inhibit fibrillar 
collagen turnover[3]. Stimulatory molecules include 
angiotensin II, aldosterone, transforming growth factor-beta 
and endothelin; inhibitory molecules include bradykinin, 
prostaglandins, nitric oxide and natriuretic peptides. An 
excess of stimulators, absolute (due to over-production) or
relative (due to a deficit in inhibitor formation), can promote 
fibrosis. 
Genetic factors 
Preliminary data suggest that hypertensive myocardial 
fibrosis may also be under genetic control. In a recent 
study[ill, we investigated whether Al166C angiotensin II 
type 1 receptor (AT1) polymorphism influences the ability 
of losartan to inhibit synthesis of collagen type I and to 
bring about regression of myocardial fibrosis in patients 
with hypertensive heart disease. Patients were genotyped 
for the A s 166C AT 1 receptor polymorphism and divided into 
two subgroups: AA and AC/CC. Baseline demographic and 
haemodynamic parameters were comparable in the two 
groups of patients. However, collagen volume fraction was 
higher in AA patients than i  AC/CC patients (P < 0.05). 
Detrimental impact 
Myocardial fibrosis predisposes to heart failure (Fig. 2), 
diminished coronary reserve and ventricular arrhythmias, 
and may thereby increase the risk for adverse cardiovascular 
events in patients with hypertensive heart disease. 
Various clinical and experimental studies have 
demonstrated the importance of fibrosis in causing tissue 
stiffness. As reviewed elsewhereC12J, these studies addressed 
the following: the presence of fibrosis in the hypertrophied 
ventricle with abnormal stiffness; the importance of fibrosis 
in causing abnormal myocardial stiffness, with or without 
cardiomyocyte hypertrophy; whether preventing fibrosis 
would preserve normal tissue stiffness; and whether 
regression of fibrosis would normalize tissue stiffness in 
hypertrophied ornon-hypertrophied ventricles. As a result of 
those studies, the following broad statement can be made03J. 
A two- to threefold increase in collagen volume fraction 
increases diastolic stiffness (or diastolic dysfunction), 
whereas ystolic stiffness is preserved. A fourfold or greater 
rise in collagen volume fraction is associated with an 
additional rise in diastolic stiffness and an increase in 
systolic stiffness that may facilitate systolic dysfunction. 
This statement is supported by several clinical findings. 
Sugihara et a/.[ 14] and Ohsato et al.[ 15] reported that, in 
hypertensive patients, collagen volume fraction was the 
most significant factor related to diastolic dysfunction, as 
assessed using Doppler echocardiography. Furthermore, in 
hypertensive patients, L6pez et a/.[ 1°1 found an inverse 
correlation between collagen volume fraction and Doppler 
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Figure 2 Proposed detrimental 
consequences of myocardial fibrosis 
on left ventricular (LV) function in 
patients with arterial hyper- 
tension. 
mitral A wave deceleration time (an index of left ventricular 
distensibility). 
Recently, Brilla eta/. [91 reported that, in patients with 
essential hypertension, chronic treatment with the 
angiotensin-converting enzyme (ACE) inhibitor lisinopril 
reduced collagen volume fraction and improved left 
ventricular diastolic function. Those changes were 
independent ofregression in left ventricular hypertophy. 
An inverse relationship has been found between left 
ventricular ejection fraction a d collagen volume fraction in 
hypertensive patients[16]. Furthermore, that study found that 
systolic function was preserved when moderate fibrosis 
(collagen volume fraction 5-10%) was present, but declined 
when fibrosis became more severe. 
Additional epidemiological nd clinical data strengthen 
the potential relevance of these findings. Diastolic heart 
failure accounts for 30-50% of congestive heart failure in 
clinical practice, and is mainly caused by hypertensive h art 
disease[17]. Diastolic heart failure has a significant effect on 
mortality (5-year mortality rate of 25-35%) and morbidity 
(1-year readmission rate of 50%)[lS]. Exercise-induced 
systolic dysfunction in hypertensive patients with left 
ventricular hypertrophy has been found to arise 
predominantly from impaired diastolic filling, leading to 
insufficient augmentation of end-diastolic filling during 
exercise to maintain systolic function[19]. Recent findings in 
patients with hypertensive pulmonary oedema and normal 
left ventricular ejection fraction after treatment[ 2°1 indicate 
that pulmonary congestion was probably due to isolated, 
transient diastolic dysfunction, with increases in both left 
ventricular end-diastolic pressure and left atrial pressure. 
Schwartzkopff eta/.[ 21] demonstrated that, in hyper- 
tensive patients with reduced coronary flow reserve, total 
and peri-vascular collagen volume fraction is correlated 
with the increased minimal coronary resistance. Further- 
more, the same group showed that, in hypertensive patients, 
long-term therapy with the ACE inhibitor perindopril 
induces adecrease in coronary resistance and improvement 
in coronary reserve, associated with significant regression 
of peri-arteriolar fibrosis[221. 
Finally, McLenachan and Dargie[231 analysed possible 
correlates of left ventricular arrhythmias in patients with 
hypertensive heart disease. They found that patients with 
arrhythmias had higher left ventricular mass and collagen 
volume fraction than did patients without arrhythmias. 
Ejection fraction and the frequency of coronary vessels with 
significant (>50%) stenosis weresimilar in the two groups of 
patients. Thus, the high incidence of arrhythmias in patients 
with hypertensive h art disease cannot entirely be attributed 
to coexistent coronary artery disease or to left ventricular 
dysfunction. On the contrary, it may be related to fibrosis 
and the adaptive phenotypic changes in membrane proteins 
associated with cardiomyocyte hypertrophy. 
Non-invasive detection 
Because of the adverse ffects of myocardial fibrosis in 
patients with hypertensive heart disease, determining the 
extent of collagen accumulation i  tissue may be helpful in 
predicting clinical outcome. It may also assist in designing 
strategies to prevent or even reverse the development of
fibrosis. 
Although endomyocardial biopsy is a simple and safe 
outpatient procedure, it is nevertheless an invasive 
methodology with obvious limitations for widescale 
application. Non-invasive m asures of cardiac fibrosis (i.e. 
ultrasound tissue characterization and biochemical monitor- 
ing of collagen turnover) are therefore desirable (Fig. 3). 
Studies conducted in humans with various disorders 
involving myocardial fibrosis[24,251 have shown a promising 
correlation between echo-reflectivity and histologically 
assessed collagen content. Moreover, Ciulla et a/.[261 
demonstrated a irect correlation between collagen volume 
fraction and echo amplitude in patients with hypertensive 
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Figure 3 Proposed algorithm for detection and 
management of myocardial fibrosis in patients with 
arterial hypertension. DD=diastolic dysfunction; LVH= 
left ventricular hypertrophy; PIP=pro-collagen type I 
carboxyl-terminal pro-peptide; SD=systolic dysfunction. 
heart disease, suggesting that collagen content is the major 
determinant of regional echo intensity. Other studies[271 have 
also demonstrated alterations in the pattern of myocardial 
reflectivity in patients with hypertensive heart disease, 
especially in those with severe left ventricular hypertrophy. 
Radioimmunoassays of various serological markers of 
collagen type I and type III turnover have also shown 
promise in clinical studies in patients with arterial 
hypertension. Pro-collagen type I carboxyl-terminal pro- 
peptide (PIP) is a marker of collagen type I synthesis. In 
several studies, we found that serum concentrations of PIP 
were significantly higher in patients with hypertensive heart 
disease than in nonnotensive control individuals[2,~0,281. We 
also found that serum PIP concentrations correlated irectly 
with collagen volume fraction in patients with hypertensive 
heart disease[21. 
Using receiver operating characteristic urves, we 
calculated that a cutoffof 127 gg.  1 ~ for PIP provided 78% 
specificity and 75% sensitivity for predicting severe 
myocardial fibrosis, with a relative risk of 4.80 (95% 
confidence interval 1.19-10.30). Furthermore, when a cutoff 
of 126 gg.  1-1 for PIP and 205 ms for deceleration time 
were combined, specificity for predicting severe myocardial 
fibrosis was maintained, and sensitivity rose to 100% with a 
relative risk of 8-50 (95% confidence interval 2-31-31-25). 
In another study[l°], we observed a strong association 
between treatment-induced changes in collagen volume 
fraction and treatment-induced changes in serum PIP in 
patients with hypertensive heart disease. 
Management: 
potential for cardioreparation 
Reparation of pathological remodelling  hypertensive 
heart disease focuses on regression of fibrosis and reduction 
in the associated risk for cardiovascular events (Fig. 3)[29]. A
cardioreparative agent should counteract he imbalance 
between inhibitors and stimulators of turnover of collagen 
types I and II1. Antihypertensive agents that appear to meet 
this requirement include ACE inhibitors, AT 1 antagonists, 
aldosterone antagonists and vasopeptidase inhibitors. 
The cardioreparative concept has been proved clinically 
in three recent, relatively small, prospective trials in patients 
with biopsy-proved myocardial fibrosis. Schwartzkopff et 
al.[221 treated 14 patients with essential hypertension for 
12 months with the ACE inhibitor perindopril. Treatment 
was associated with structural repair of coronary arterioles, 
characterized mainly by the regression of peri-arteriolar 
fibrosis, and was associated with a marked improvement in
coronary reserve. Brilla et al.[9] randomized 35 patients with 
hypertensive heart disease to receive either the ACE 
inhibitor lisinopril or the diuretic hydrochlorothiazide for 6 
months. Only patients randomized to lisinopril had a 
significant reduction in collagen volume fraction, which 
was associated with improvement in diastolic dysfunction. 
Finally, Ldpez et a/.[10] studied 37 patients with 
hypertensive heart disease. After randomization, 21 patients 
were assigned to receive the AT 1 receptor antagonist 
losartan, and 16 to the calcium channel blocker amlodipine 
for 12 months. In losartan-treated patients, collagen volume 
fraction decreased and left ventricular distensibility 
increased significantly. In contrast, those parameters 
remained unchanged in amlodipine-treated patients. 
Conclusion 
Myocardial fibrosis is a key histological constituent of 
myocardial remodelling in hypertensive heart disease. 
Hypertensive myocardial fibrosis has been shown to promote 
abnormalities of cardiac function that may adversely affect 
the clinical outcome of hypertensive patients. Development 
of non-invasive tools for monitoring myocardial fibrosis and 
pharmacological strategies to promote its regression could 
therefore be of particular relevance in the clinical 
management of patients with hypertensive h art disease. 
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